Three medications for bladder, liver and renal cancers will be listed on the PBS from 1 March. The anti-PD-1 immunotherapy pembrolizumab (Keytruda) will become available for patients with locally advanced or metastatic urothelial cancer, the government has announced. More than 430 patients a year are expected to be eligible for treatment with pembrolizumab as monotherapy for the ...
PBS listings for kidney, liver and bladder cancer drugs
By Michael Woodhead
27 Feb 2019